Basal

Basal Therapies to host PJs & Prizes: A Grand Opening on Saturday, October 30th 9-11am

Retrieved on: 
Friday, October 22, 2021

Participants are encouraged to wear their favorite pajamas, rather than costumes, while they enjoy story time, crafts, games, and prizes.

Key Points: 
  • Participants are encouraged to wear their favorite pajamas, rather than costumes, while they enjoy story time, crafts, games, and prizes.
  • Open to the community, PJs & Prizes: A Grand Opening will give Frederick-area families the opportunity to tour the new Basal Therapies location at Riverside, along with the brand new Basal Preschool.
  • Basal Therapies is a provider of pediatric therapy services to area children and families.
  • Basal Therapies has served the Frederick community and surrounding area since 2020 and has two offices in Frederick.

Amalgam Rx™ Receives CE Mark for Basal Insulin Titration

Retrieved on: 
Wednesday, June 16, 2021

Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, is announcing it has achieved the Conformit Europenne (CE) Mark for its insulin titration application, iSage Rx and its white-labeled variants.

Key Points: 
  • Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, is announcing it has achieved the Conformit Europenne (CE) Mark for its insulin titration application, iSage Rx and its white-labeled variants.
  • View the full release here: https://www.businesswire.com/news/home/20210616005524/en/
    Amalgam Rx Receives CE Mark for Basal Insulin Titration (Graphic: Business Wire)
    With this CE Mark, iSage Rxs capacity to support the titration of all basal insulins and enable connectivity to the leading Bluetooth-enabled blood glucose meters from Roche, Lifescan, and Ascensia, is now cleared for the European market.
  • In early clinical studies, the iSage Rx app has demonstrated the ability to improve patients glucose levels by helping them reach the appropriate level of basal insulin.
  • Amalgam is the manufacturer of the iSage Rx app and white-labeled variants, the first prescription-only mobile application for the automated titration of all brands of basal insulin to receive market authorization in the United States, EU, and Brazil.

CeQur Raises $115 Million Series C5 Financing to Support Commercialization and Scale-Up of Automated Manufacturing for CeQur Simplicity Wearable Insulin-Delivery Device

Retrieved on: 
Tuesday, April 13, 2021

One Simplicity patch holds up to 200 units of rapid-acting insulin administered in two-unit increments and replaces, on average, nine mealtime injections over three days.

Key Points: 
  • One Simplicity patch holds up to 200 units of rapid-acting insulin administered in two-unit increments and replaces, on average, nine mealtime injections over three days.
  • Clinical research has shown that nearly 90% of patients using CeQur Simplicity reported following their insulin regimen better as compared to MDI.
  • 2012;29(5):682-689.\niii Based on global incidence and prevalence of patients on basal-bolus therapy and CeQur management estimates.\niv Johnson ML, Dreon DM, Levy BL, et al.
  • Paper presented at: 54th Annual Meeting of the European Association for the Study of Diabetes; October 1-5, 2018; Berlin, Germany.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210413005506/en/\n'

Welldoc Submits 510(k) for Bolus and Premixed Insulin Titration Program as Part of BlueStar®

Retrieved on: 
Monday, December 14, 2020

With the filing, BlueStar looks to add bolus and premixed insulin titration for type 2 diabetes to its comprehensive diabetes platform.

Key Points: 
  • With the filing, BlueStar looks to add bolus and premixed insulin titration for type 2 diabetes to its comprehensive diabetes platform.
  • In June, Welldoc announced FDA clearance for the BlueStar Insulin Adjustment Program for basal insulin titration.
  • This current submission would expand insulin dosing support to include most types of insulin.
  • By going digital, our new bolus and premixed insulin titration program goes beyond the pencil and paper processes we traditionally have relied upon to make the process of adjusting insulin easier and safer.

Oramed's Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients

Retrieved on: 
Tuesday, September 15, 2020

Forty-one health care providers, including 22 endocrinologists and 19 primary care physicians, nurse practitioners, physician assistants and certified diabetes educators were surveyed.

Key Points: 
  • Forty-one health care providers, including 22 endocrinologists and 19 primary care physicians, nurse practitioners, physician assistants and certified diabetes educators were surveyed.
  • There was strong support among these health care providers for use of oral insulin with T2D patients early in the treatment process through a primary care physician before the need for injectable insulin and before the patient is moved to an endocrinologist for diabetes care.
  • Overall, health care providers stated they would "strongly recommend oral insulin" for:
    T2D patients currently on oral medication;
    T2D patients who are candidates for insulin; and
    T2D patients who are candidates for basal insulin.
  • Oramed's Chief Executive Officer, Nadav Kidron, commented, "This latest market survey further confirms the value of our oral insulin capsule.

Global Large Volume Wearable Injectors Market 2020-2030: Focus on Bolus, Basal and Continuous Delivery Devices - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 23, 2020

The "Large Volume Wearable Injectors Market (5th Edition), 2020-2030: Focus on Bolus, Basal and Continuous Delivery Devices" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Large Volume Wearable Injectors Market (5th Edition), 2020-2030: Focus on Bolus, Basal and Continuous Delivery Devices" report has been added to ResearchAndMarkets.com's offering.
  • One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for large volume wearable injectors.
  • What are the prevalent trends within the competitive landscape of large volume wearable injectors for delivery of non-insulin drugs?
  • What are the types of drug candidates that are suited for delivery via large volume wearable injectors?

Glytec’s Glucommander Software Combined with Continuous Glucose Monitoring Enables Patients with Diabetes to Improve Time in Range by More than 25% in Only Four Weeks

Retrieved on: 
Monday, June 15, 2020

The study evaluated 25 adults who used the Abbott Freestyle Libre CGM system and Abbott LibreLink app on their mobile phone.

Key Points: 
  • The study evaluated 25 adults who used the Abbott Freestyle Libre CGM system and Abbott LibreLink app on their mobile phone.
  • Patient data was provided to Glytecs Glucommander software the only cloud-based, FDA-cleared solution for outpatient basal-bolus insulin titration.
  • All participants met the criteria of living with Type 2 diabetes, reporting A1C levels > 8.0%, and owning a smartphone capable of running the LibreLink app.
  • And in a post-COVID world, removing the need for multiple in-person visits is an enormous benefit for high-risk patients living with diabetes.

Welldoc Receives FDA Clearance for Long-Acting Insulin Support for Award-Winning Digital Health Solution BlueStar®

Retrieved on: 
Wednesday, June 3, 2020

The Insulin Adjustment Program (IAP), supports the process of basal insulin titration by health care providers for adults with type 2 diabetes.

Key Points: 
  • The Insulin Adjustment Program (IAP), supports the process of basal insulin titration by health care providers for adults with type 2 diabetes.
  • Patients who are prescribed IAP as part of BlueStar, will benefit from the ease of real time adjustments to their insulin.
  • BlueStar is the only FDA approved and reimbursable Software as a Medical Device that works with a patient's existing devices.
  • BlueStar, the first FDA-cleared digital health solution, guides individuals through the complicated journey of living with diabetes by enabling them to self-manage their conditions and enhancing connections to their health care team.

Tandem Diabetes Care Announces FDA Designation of Basal-IQ Technology as an Interoperable Automated Glycemic Controller

Retrieved on: 
Monday, March 2, 2020

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance of its Basal-IQ technology as an interoperable automated glycemic controller (iAGC).

Key Points: 
  • Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance of its Basal-IQ technology as an interoperable automated glycemic controller (iAGC).
  • This is the second system to receive iAGC designation by the FDA, following the Companys clearance of the t:slim X2 insulin pump with Control-IQ technology in December 2019.
  • Tandem Diabetes Care, Inc. ( www.tandemdiabetes.com ) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience.
  • Tandem manufactures and sells the t:slim X2 insulin pump with Basal-IQ technology and the t:slim X2 insulin pump with Control-IQ technology.

Advanced Hybrid Closed Loop System Early Feasibility Data on Patients Undergoing Unannounced Meal Challenges Shows Promising Results

Retrieved on: 
Monday, February 24, 2020

Here is a recap of the major scientific data presentations on Medtronic innovation that took place at ATTD 2020:

Key Points: 
  • Here is a recap of the major scientific data presentations on Medtronic innovation that took place at ATTD 2020:
    Missed and Late Meal Boluses with Faster Acting Insulin Aspart (Fiasp)vs. Insulin Aspart Using the Medtronic Advanced Hybrid Closed Loop System
    The advanced hybrid closed loop (AHCL)systemis designed to combine automated basal (background) insulin delivery with automatic correctionboluses.
  • The AHCL system will also feature an adjustable target glucose as low as 100 mg/dL (5.5mmol/L), the lowest amongst any automated insulin delivery system, for the first time.
  • The combined automated basal and correction bolus of the AHCL system is designed to help accommodate for inexact carbohydrate counting or occasionally missed meal dose.
  • Adult pump-experienced participants with type 1 diabetes began using the advanced hybrid closed loop system and were randomly assignedFiaspor insulin aspart over two stages (6-weeks duration each).